Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 2, 2008, Pages 295-298

  Yildirim, Yesim ^a   Ozyilkan, Ozgur ^a   Bilezikci, Banu ^a   Akcali, Zafer ^a   Haberal, Mehmet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Cyclooxygenese 2; Hepatocellular carcinoma; Survival

Indexed keywords

CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

AGED; ARTICLE; ENZYME IMMUNOASSAY; ENZYMOLOGY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VIROLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 59849117184     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bae SH, Jung ES, Park YM, et al.(2001). Expression of cyclooxygenase-2 in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res, 7, 1410-8.
2. Barlett DB, Carr BI, Marsh JW (2005). Cancer of the liver. In 'Cancer Principles and Practice of Oncology'. DeVita VT, Hellman S, Rosenberg SA eds. Philadelphia. Lipincott William, Wilkins, pp986-1009.
3. Chen TH, Tseng LM, Chau GY, et al. (2001). Clinicopathologic and prognostic differences between patients with hepatitis B- and C-related respectable hepatocelluler carcinoma. J Formos Med Assoc, 100, 443-8.
4. Cheng AS, Chan HL, To KF, et al. (2004). Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus associated hepatocellular carcinoma. Int J Oncol, 24, 853-60.
5. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, Dubois RN (2005). Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacological targets for chemoprevention. J Clin Oncol, 23, 254-66.
6. Iwamoto A, Ikeguchi M, Matsumoto S, et al.(2006). Tumor cyclooxygenase gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumori, 92, 130-3.
7. Koga H, Sakisaka S, Ohishi M, et al. (1999). Expression of cyclooxygenease-2 in human heaptocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 29, 688-96.
8. Kondo M, Yamamato H, Nagano H, et al.(1999). Increased expression of COX-2 in nontumoral liver tissue is associated with shorter disease-free survival in patients with heaptocellular carcinoma. Clin Cancer Res, 5, 4005-12.
9. McGinty A, Chang YW, Sorokin A, Bokemeyer D, Dunn MJ (2000). Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor differentiated PC12 cells. J Biol Chem, 275, 12095-101.
10. Morinaga S, Yamamato Y, Nogughi Y, et al.(2002). Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol, 17, 1110-5.
11. Okuda K (1992). Hepatocellular carcinoma: recent progress. Hepatology, 15, 948-63.
12. Roayaie S, Haim MB, Emre S, et al.(2000). Comparision of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Western experience. Ann Surg Oncol, 7, 764-70.
13. Sung YK, Hwang SY, Kim JO, et al.(2003). The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells, 17, 35-8.
14. Tang TCM, Poon RTP, Fan ST (2005). The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma. Biomed Pharmacother, 59, S311-6.
15. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000). Host cyclooxygenase-2 modulates carcinoma growth. J Clin Investig, 105, 1589-94.